Swedish Orphan Biovitrum Dirección

Dirección controles de criterios 3/4

Actualmente no disponemos de información suficiente sobre el CEO.

Información clave

Guido Oelkers

Chief Executive Officer (CEO)

kr48.9m

Compensación total

Porcentaje del salario del CEO	25.1%
Permanencia del CEO	7yrs
Participación del CEO	0.1%
Permanencia media de la dirección	5.3yrs
Promedio de permanencia en la Junta Directiva	3.5yrs

Actualizaciones recientes de la dirección

Recent updates

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Guido Oelkers en comparación con los beneficios de Swedish Orphan Biovitrum?
Fecha	Compensación total	Salario	Ingresos de la empresa
Mar 31 2024	n/a	n/a	kr2b
Dec 31 2023	kr49m	kr12m	kr2b
Sep 30 2023	n/a	n/a	kr3b
Jun 30 2023	n/a	n/a	kr3b
Mar 31 2023	n/a	n/a	kr3b
Dec 31 2022	kr47m	kr11m	kr3b
Sep 30 2022	n/a	n/a	kr2b
Jun 30 2022	n/a	n/a	kr3b
Mar 31 2022	n/a	n/a	kr3b
Dec 31 2021	kr42m	kr10m	kr3b
Sep 30 2021	n/a	n/a	kr3b
Jun 30 2021	n/a	n/a	kr3b
Mar 31 2021	n/a	n/a	kr3b
Dec 31 2020	kr33m	kr10m	kr3b
Sep 30 2020	n/a	n/a	kr3b
Jun 30 2020	n/a	n/a	kr3b
Mar 31 2020	n/a	n/a	kr4b
Dec 31 2019	kr33m	kr10m	kr3b
Sep 30 2019	n/a	n/a	kr3b
Jun 30 2019	n/a	n/a	kr3b
Mar 31 2019	n/a	n/a	kr3b
Dec 31 2018	kr26m	kr9m	kr2b
Sep 30 2018	n/a	n/a	kr2b
Jun 30 2018	n/a	n/a	kr2b
Mar 31 2018	n/a	n/a	kr1b
Dec 31 2017	kr16m	kr5m	kr1b

Compensación vs. Mercado: La compensación total de Guido($USD4.47M) está por encima de la media de empresas de tamaño similar en el mercado German ($USD3.42M).

Compensación vs. Ingresos: La compensación de Guido ha sido consistente con los resultados de la empresa en el último año.

CEO

Guido Oelkers (58 yo)

7yrs

Permanencia

kr48,883,000

Compensación

Dr. Guido Oelkers is a Director of Dova Pharmaceuticals Inc. since November 12, 2019. Dr. Oelkers has been the Chief Executive Officer and President at Swedish Orphan Biovitrum AB since May 22, 2017. He se...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Guido Oelkers	CEO & President	7yrs	kr48.88m	0.11% SEK 9.0m
Henrik Stenqvist	Chief Financial Officer	5.8yrs	sin datos	0.015% SEK 1.2m
Torbjörn Hallberg	General Counsel & Head of Legal Affairs	5.3yrs	sin datos	0.0079% SEK 642.4k
Daniel Rankin	Head of Strategy & Corporate Development	2.3yrs	sin datos	0.0058% SEK 472.4k
Lena Bjurner	Head of Human Resources	1.3yrs	sin datos	sin datos
Armin Reininger	Senior Scientific & Medical Advisor	7.3yrs	sin datos	0.0047% SEK 384.1k
Norbert Oppitz	Head of International	6.6yrs	sin datos	0.010% SEK 836.1k
Sofiane Fahmy	Head of Europe	5.3yrs	sin datos	0.0078% SEK 638.3k
Duane Barnes	Head of North America	3.3yrs	sin datos	sin datos
Mahmood Ladha	Head of Strategic Transformation Operations	no data	sin datos	0.0018% SEK 150.4k
Christine Wesstrom	Head of Technical Operations	2.2yrs	sin datos	0.0030% SEK 248.5k
Lydia Abad-Franch	Senior VP	1.3yrs	sin datos	sin datos

5.3yrs

Permanencia media

55.5yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de B6E es experimentado (5.3 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Hans Wigzell	Chairman of Scientific Advisory Board	23.3yrs	kr158.00k	sin datos
Helena Saxon	Director	13.1yrs	kr828.00k	0.0059% SEK 480.6k
Anders Ullman	Director	less than a year	kr463.00k	0.00088% SEK 71.9k
Stephen O'Rahilly	Member of Scientific Advisory Board	no data	sin datos	sin datos
Ralf Pettersson	Member of Scientific Advisory Board	no data	sin datos	sin datos
Stefan Del Prato	Member of Scientific Advisory Board	no data	sin datos	sin datos
Jonathan Sanders Arch	Member of Scientific Advisory Board	no data	sin datos	sin datos
Annette Clancy	Independent Chairman	10yrs	kr770.00k	0.0010% SEK 81.7k
Staffan Schuberg	Independent Director	4yrs	kr827.00k	0.0019% SEK 156.1k
Filippa Stenberg	Director	3yrs	kr673.00k	0.00015% SEK 12.3k
Katy Mazibuko	Employee Representative Director	1.3yrs	sin datos	sin datos
Christophe Bourdon	Independent Director	less than a year	kr433.00k	sin datos

3.5yrs

Permanencia media

53.5yo

Promedio de edad

Junta con experiencia: La junta directiva de B6E se considera experimentada (3.4 años de antigüedad promedio).

Swedish Orphan Biovitrum Dirección

Dirección controles de criterios 3/4

Información clave

Actualizaciones recientes de la dirección

Head of Technical Operations recently sold €501k worth of stock

Swedish Orphan Biovitrum AB (Publ) Announces Resignation of Bo Jesper Hansen as Chairman of the Board and Board Member

Senior Scientific & Medical Advisor recently sold €1.4m worth of stock

Swedish Orphan Biovitrum AB (publ), Annual General Meeting, May 14, 2024

Sobi Appoints Lydia Abad-Franch as Head of R&D and Chief Medical Officer

Independent Chairman recently bought €1.0m worth of stock

Recent updates

Swedish Orphan Biovitrum AB (Publ) Provides Earnings Guidance for 2024

Swedish Orphan Biovitrum AB (publ) to Report Q4, 2024 Results on Feb 05, 2025

Full year 2023 earnings released: EPS: kr7.47 (vs kr8.92 in FY 2022)

Swedish Orphan Biovitrum AB (publ) to Report Fiscal Year 2023 Final Results on Apr 02, 2024

Head of Technical Operations recently sold €501k worth of stock

Full year 2023 earnings released: EPS: kr7.47 (vs kr8.92 in FY 2022)

Swedish Orphan Biovitrum AB (Publ) Provides Revenue Guidance for the Year 2024

Swedish Orphan Biovitrum AB (Publ) Announces Resignation of Bo Jesper Hansen as Chairman of the Board and Board Member

Senior Scientific & Medical Advisor recently sold €1.4m worth of stock

Swedish Orphan Biovitrum AB (publ), Annual General Meeting, May 14, 2024

Third quarter 2023 earnings released: EPS: kr0.30 (vs kr1.52 in 3Q 2022)

Sobi and Apellis Pharmaceuticals, Inc. Announce Positive Results from Phase 2 NOBLE Results of Pegcetacoplan in Post-Transplant Recurrence of Primary IC-MPGN and C3G

Sobi Appoints Lydia Abad-Franch as Head of R&D and Chief Medical Officer

Sanofi S.A. and Sobi Announce Once-Weekly ALTUVIIIO Approved in Japan as A New Class of Factor VIII Therapy for Hemophilia A

Swedish Orphan Biovitrum AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 6.023593 billion.

Swedish Orphan Biovitrum AB (publ) to Report Q3, 2024 Results on Oct 24, 2024

New major risk - Financial position

Second quarter 2023 earnings released: EPS: kr0.75 (vs kr0.87 in 2Q 2022)

Swedish Orphan Biovitrum AB (publ) (OM:SOBI) completed the acquisition of CTI BioPharma Corp. (NasdaqCM:CTIC) from a group of shareholders.

European Medicines Agency Validates Sobi's Marketing Authorisation Application for Efanesoctocog Alfa for Treatment of Haemophilia A

Independent Chairman recently bought €1.0m worth of stock

Less than half of directors are independent

Swedish Orphan Biovitrum AB (publ) (OM:SOBI) entered into a definitive agreement and plan of merger to acquire CTI BioPharma Corp. (NasdaqCM:CTIC) from a group of shareholders for $1.2 billion.

Swedish Orphan Biovitrum AB (Publ) Approves Election of Christophe Bourdon and Anders Ullman as Members of the Board

Full year 2022 earnings released: EPS: kr8.92 (vs kr9.08 in FY 2021)

Insider recently sold €1.2m worth of stock

Head of Europe recently sold €1.4m worth of stock

CEO & President recently sold €2.2m worth of stock

Full year 2022 earnings released: EPS: kr8.92 (vs kr9.08 in FY 2021)

Swedish Orphan Biovitrum AB (Publ) Provides Earnings Guidance for 2023

Swedish Orphan Biovitrum AB (Publ) Announces Executive Changes

ADC Therapeutics SA and Swedish Orphan Biovitrum AB Announce the European Commission Approval of Zynlonta® (Loncastuximab Tesirine)

Sobi North America, the North American Affiliate of Swedish Orphan Biovitrum AB Announces That U.S. Food and Drug Administration Issues Emergency Use Authorization for Kineret® (Anakinra) for the Treatment of Covid-19-Related Pneumonia

Swedish Orphan Biovitrum AB (Publ)'s Chairman of the Board Håkan Björklund Will Not Be Available for Re-Election At the Annual General Meeting 2023

Swedish Orphan Biovitrum AB (publ) to Report Q3, 2023 Results on Oct 26, 2023

Third quarter 2022 earnings released: EPS: kr1.52 (vs kr1.60 in 3Q 2021)

ADC Therapeutics and Sobi Announce ZYNLONTA® (loncastuximab tesirine) Receives Positive CHMP Opinion in Europe for the Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma

Sanofi and Sobi Announce US Food and Drug Administration Accept Priority Review the Biologics License Application for efanesoctocog alfa

Second quarter 2022 earnings released: EPS: kr0.87 (vs kr0.91 in 2Q 2021)

Swedish Orphan Biovitrum AB (publ) Provides Revenue Guidance for the Year 2022

Apellis Pharmaceuticals, Inc. and Sobi(R) Report New Data Reinforcing the Robust Efficacy and Safety Profile of EMPAVELI (pegcetacoplan) for PNH at EHA 2022 Congress

Apellis Pharmaceuticals, Inc. and Sobi Announces First Patient Dosed in Phase 3 VALIANT Study of Pegcetacoplan for IC-MPGN and C3G, Rare Kidney Diseases with High Unmet Medical Need

FDA Grants efanesoctocog alfa Breakthrough Therapy Designation for Hemophilia A by Sanofi and Sobi

Swedish Orphan Biovitrum AB (publ) Elects Bo Jesper Hansen as New Board Member

First quarter 2022 earnings released: EPS: kr1.84 (vs kr2.36 in 1Q 2021)

Sanofi and Swedish Orphan Biovitrum AB Announce Positive Topline Results from the Pivotal XTEND-1 Phase 3 Study

Gamifant (Emapalumab) Recommends for Approval in China for Treatment of Primary Haemophagocytic Lymphohistiocytosis (HLH)

Swedish Orphan Biovitrum AB (publ), Annual General Meeting, May 10, 2022

Kineret® (Anakinra) Receives Positive Opinion from the Committee for Medicinal Products for Human Use of the European Medicines Agency for Treatment of Patients with Covid-19 Pneumonia

Apellis Pharmaceuticals, Inc. and Swedish Orphan Biovitrum AB (Publ) Announce EU Approval of Aspaveli® (Pegcetacoplan) for Treatment of PNH

Apellis Pharmaceuticals, Inc. and Swedish Orphan Biovitrum AB (publ) Report Empaveli™ Demonstrated Sustained Normalization of Clinical Measures in a Broad PNH Patient Population

Advent International Corporation and GIC Special Investments Pte. Ltd. cancelled the acquisition of Swedish Orphan Biovitrum AB (publ) (OM:SOBI) from Investor AB (publ) (OM:INVE A), AP Fonden 4 and others.

Investor sentiment deteriorated over the past week

Head of Technical Operations recently bought €134k worth of stock

Third quarter 2021 earnings released: EPS kr1.60 (vs kr0.94 in 3Q 2020)

Swedish Orphan Biovitrum AB (publ) Publishes Positive Phase 3 Anakinra Study Results in Patients with COVID-19 Pneumonia

Nature Medicine Publishes Phase 3 Anakinra Study Results in Patients with Covid-19 Pneumonia

Investor sentiment improved over the past week

Orphan Biovitrum Jumps After Bloomberg Report of Potential Takeover

Second quarter 2021 earnings released: EPS kr0.91 (vs kr0.96 in 2Q 2020)

Apellis Pharmaceuticals, Inc. and Swedish Orphan Biovitrum AB (Publ) Report Positive Top-Line Results from the Phase 3 Prince Study of EMPAVELI™ (pegcetacoplan) in Treatment-naïve Patients with PNH

CEO & President recently bought €805k worth of stock

Swedish Orphan Biovitrum AB (publ) Announces Early Use of Anakinra Reduces Risk of Mortality for Patients with Covid-19 Pneumonia, Reduces ICU Admission and Increases Likelihood of Full Recovery

CEO & President recently bought €419k worth of stock

Director has left the company

First quarter 2021 earnings released: EPS kr2.36 (vs kr4.02 in 1Q 2020)

Swedish Orphan Biovitrum AB (Publ) and Hellenic Institute for the Study Announce Positive Top Line Results from the Investigator-Sponsored Save-More Study

Swedish Orphan Biovitrum AB (Publ) Provides Revenue Guidance for the Full Year 2021

Full year 2020 earnings released: EPS kr11.01 (vs kr11.29 in FY 2019)